1. Emergent to make Calgary-based Providence Therapeutics' potential COVID-19 vaccine  CBC.ca
  2. Chinese firm buys Canada mRNA vaccine tech in US$500M deal  BNN
  3. Providence licenses mRNA technology to China's Everest in $100-million deal  Financial Post
  4. Everest to bring Canada’s Providence Therapeutics’ COVID-19 vaccine to China  Global News
  5. 'Abysmal': Canadian vaccine maker slams feds on lack of support  BNN
  6. View Full coverage on Google News
Emergent BioSolutions Inc. signed a five-year agreement with Calgary-based biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.Emergent BioSolutions Inc. signed a five-year agreement with Calgary-based biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.

www.cbc.ca

Chinese biopharma firm Everest Medicines Ltd. will license an mRNA COVID-19 vaccine from Canada’s Providence Therapeutics Holdings Inc., as companies try to bring the most effective inoculation platform into China despite its apparent resistance to western shots.

Chinese firm buys Canada mRNA vaccine tech in US$500M deal - BNN Bloomberg

Calgary-based Providence has secured rights to stock and profit sharing totalling up to $400 million, plus royalties, if certain milestones are met

Providence licenses mRNA technology to China's Everest in $100-million deal | Financial Post

Providence licenses mRNA technology to China's Everest in $100-million deal | Financial Post

Everest Medicines signed a licence agreement with Providence Therapeutics to make and sell the biotechnology company's potential mRNA COVID vaccines in some Asian countries. Everest Medicines signed a licence agreement with Providence Therapeutics to make and sell the biotechnology company's potential mRNA COVID vaccines in some Asian countries.

Everest to bring Canada’s Providence Therapeutics’ COVID-19 vaccine to China | Globalnews.ca

Emergent BioSolutions and Providence Therapeutics inked a five-year, $90 million deal for the contract drug manufacturer to support Providence’s development and manufacturing of its mRNA COVID-19 vaccine candidate.Emergent BioSolutions and Providence Therapeutics inked a five-year, $90 million deal for the contract drug manufacturer to support Providence’s development and manufacturing of its mRNA COVID-19 vaccine candidate.

Emergent, after J&J woes, inks $90M deal to help produce Providence Therapeutics' mRNA COVID-19 vaccine | FiercePharma

The Chinese mRNA sector is heating up. In the wake of megarounds by its compatriots, Everest Medicines has bought its way into the mRNA COVID-19 vaccine space through a deal with Providence Therapeutics.The Chinese mRNA sector is heating up. In the wake of megarounds by its compatriots, Everest Medicines has bought its way into the mRNA COVID-19 vaccine space through a deal with Providence Therapeutics.

Everest bags COVID-19 program in bid to conquer Chinese mRNA market | FierceBiotech

Everest will gain rights to Providence's vaccine in Greater China and countries that include Indonesia, Singapore and Thailand.. Read more at straitstimes.com.Business News -Everest will gain rights to Providence's vaccine in Greater China and countries that include Indonesia, Singapore and Thailand.. Read more at straitstimes.com.

Chinese firm buys Canadian mRNA vaccine rights in $670 million deal, Business News & Top Stories - The Straits Times

While almost 1 billion people have been fully vaccinated in China, the country is still lacking an mRNA shot

Chinese firm buys Canadian mRNA vaccine technology despite apparent resistance to western shots | Financial Post

Chinese firm buys Canadian mRNA vaccine technology despite apparent resistance to western shots | Financial Post

www.theglobeandmail.com

Bloomberg - Are you a robot?

Emergent BioSolutions Inc signed a five-year agreement with Canadian biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.Emergent BioSolutions Inc signed a five-year agreement with Canadian biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.

Emergent to make Providence Therapeutics potential COVID-19 vaccine | Reuters